EXPEDITED REVIEW
The Cost Effectiveness of Implantable Cardioverter-Defibrillators
Results From the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II
Jack Zwanziger, PhD*,*,
W. Jackson Hall, PhD ,
Andrew W. Dick, PhD*,
Hongwei Zhao, DSc,
Alvin I. Mushlin, MD, ScM*,
Rebecca Marron Hahn, MPH*,
Hongkun Wang, MA,
Mark L. Andrews, BBS ,
Cathleen Mooney, MS*,
Hongyue Wang, MA and
Arthur J. Moss, MD
* Community and Preventive Medicine
Biostatistics and Computational Biology
Cardiology Division of the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
Manuscript received December 4, 2005;
revised manuscript received March 2, 2006,
accepted March 16, 2006.
* Reprint requests and correspondence: Dr. Jack Zwanziger, Director, Department of Health Policy and Administration, Center for Health Sciences Research, University of Illinois at Chicago, School of Public Health, Chicago, Illinois 60612-4394 (Email: jzwanzig{at}uic.edu).
 |
Abstract
|
|---|
OBJECTIVES: We sought to evaluate the cost implications of the implantable cardioverter-defibrillator (ICD), using utilization, cost, and survival data from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
BACKGROUND: This trial showed that prophylactic implantation of a defibrillator reduces the rate of mortality in patients who experienced a previous myocardial infarction and low left ventricular ejection fraction. Given the size of the eligible population, the cost effectiveness of the ICD has substantial implications.
METHODS: Our research comprises the cost-effectiveness component of the randomized controlled trial, MADIT-II, based on utilization, cost, and survival information from 1,095 U.S. patients who were assigned randomly to receive an ICD or conventional medical care. Utilization data were converted to costs using a variety of national and hospital-specific data. The incremental cost-effectiveness ratio (iCER) was calculated as the difference in discounted costs divided by the difference in discounted life expectancy within 3.5 years. Secondary analyses included projections of survival (using three alternative assumptions), corresponding cost assumptions, and the resulting cost-effectiveness ratios until 12 years after randomization.
RESULTS: During the 3.5-year period of the study, the average survival gain for the defibrillator arm was 0.167 years (2 months), the additional costs were $39,200, and the iCER was $235,000 per year-of-life saved. In three alternative projections to 12 years, this ratio ranged from $78,600 to $114,000.
CONCLUSIONS: The estimated cost per life-year saved by the ICD in the MADIT-II study is relatively high at 3.5 years but is projected to be substantially lower over the course of longer time horizons.
|
Abbreviations and Acronyms
| | CONV = conventional therapy | | HR = hazard ratio | | ICD = implantable cardioverter-defibrillator | | iCER = incremental cost effectiveness ratio | | MADIT-II = Second Multicenter Automatic Defibrillator Implantation Trial | | QALY = quality-adjusted life years | | YOLS = years-of-life saved |
|
Several clinical trials have shown that implantable cardioverter-defibrillators (ICDs) improve survival in patients with a spectrum of heart disease (1–8). The second Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II (5), conducted in 1997 to 2002, had a relatively broad set of inclusion criteria that could have a major impact because 32,000 to 66,000 people in the U.S. annually fit these criteria (9,10). Three studies (10–12) have reported cost evaluations for MADIT-II–type patients, without use of cost information from the trial. This report combines patient outcome and economic data from the U.S. patients in the MADIT-II study and presents an analysis of the cost effectiveness of their ICD therapy.
|
Methods
|
|---|
The MADIT-II study.
Eligibility requirements for the MADIT-II study included a previous myocardial infarction and a left ventricular ejection fraction  30%, with no electrophysiological testing required. Patients were assigned randomly to receive either an ICD or conventional medical therapy (CONV), in a 3:2 ratio; approved ICD devices were those manufactured by Guidant Corporation (St. Paul, Minnesota). The enrollment procedures, clinical follow-up, and results have been described previously (5). The MADIT-II research protocol was approved by the institutional review boards of the enrolling centers; all enrolled patients gave written informed consent. Funding for the study was provided by Guidant Corporation. The authors are solely responsible for the study design, data collection, analysis, and interpretation of results.
The cost-effectiveness analysis was based on 1,095 of the 1,232 patients in the MADIT-II study, namely those from 69 U.S. centers (omitting the five European centers [n = 109], two U.S. centers [n = 14] with grossly incomplete cost data, and 14 additional patients with missing cost data). Of the 1,095 patients, there were 664 in the ICD arm and 431 in the CONV arm; 17 of the former never received an ICD, and 23 of the latter had implantations during the trial. Baseline characteristics of the patients in the cost-effectiveness substudy were much the same as for all patients (5). All-cause mortality was 90 (21%) in the CONV arm and 97 (15%) in the ICD arm (estimated hazard ratio [HR] = 0.677).
Collection of utilization information.
Patients were scheduled for follow-up visits at one and three months after randomization, at three-month intervals thereafter, and were contacted by phone during each intervening month. The information gathered at each contact (clinic or phone) included:
- • number and duration of physician office visits by specialty
- • number and type of outpatient diagnostic tests and procedures and ambulatory surgeries
- • dates and hospital name for each emergency room visit and hospitalization
- • number and duration of other health care services, including nursing home admissions, physical, speech, or occupational therapies and podiatry
- • medications taken since the last clinic visit.
At each office visit or telephone contact, patients reviewed their utilization for any period they missed. Study staff contacted the named hospitals, provided the required patient authorizations, and requested the hospital bills.
Table 1 shows the completeness of the health care utilization data collected for the MADIT-II study. The largest proportion of expenditures was for hospital services with only 17 of 530 (CONV) and 25 of 1,450 (ICD) inpatient hospital bills missing. Similarly, small proportions of other utilization data were not collected. Values for missing data were imputed; for example, when hospital bills were missing, the costs were estimated using length of stay and average cost per day for that admission type.
Calculating costs and charges.
The methods used to translate utilization data into costs were those used in Mushlin et al. (13), except that the costs for inpatient physician services were estimated by regression models using data from Medicare inpatient and physician bills. These models generated the predicted ratio of inpatient physician costs to hospital costs for each admission. The physician costs associated with an admission are this predicted ratio multiplied by its hospital costs.
Statistical methods.
Primary analyses
All primary analyses were prespecified with patients assigned to arm on an "intent-to-treat" basis. These analyses had a maximum of 3.5 years of follow-up (with data from only 18 patients beyond that) and are from a societal perspective. Costs were assembled on a daily basis, with period-specific costs (for hospitalizations, for example) spread evenly over the appropriate period.
For survival, we used follow-up information until closeout—typically a month or so beyond the formal trial termination (but before any subsequent ICD implantation). Follow-up ranged from 11 days to 55 months, averaging 22 months. Only one patient was lost to follow-up for survival information, and then for only six months. As recommended (14), both costs and survival times were discounted—with future costs and benefits worth less than current ones—to randomization using a 3% per annum discount rate. All costs are expressed in 2001 dollars.
Thirty-two patients became inactive before trial termination, resulting in a shorter follow-up period for cost analysis; only their survival status was determined at closeout. Their follow-up averaged 44% of the potential number, representing a loss of 2.2% of the total follow-up days in the study.
Arm-specific discounted mean costs and survival times and the resulting incremental cost-effectiveness ratio (iCER) and associated confidence limits were estimated by methods in (15), extended to accommodate differing follow-up times for cost and survival in some patients (16). We re-estimated the iCER by the method used in the MADIT study (17), which is similar to that in Lin et al. (18).
Projecting to a 12-year time horizon
Projecting survival
To project arm-specific survival out to 12 years, using Kaplan-Meier estimates for the first 3.5 years, we used the following life-table method. We determined the average survival probability for each of 12 successive years for a subset of the U.S. population, matched by age and gender to the MADIT-II study population, using published data for the U.S. (19). This survival curve was fit almost perfectly by a quadratic hazard rate model, with hazard rate increasing at an accelerated rate over time (reflecting aging). We assumed that CONV arm patients would likewise have a quadratic hazard rate, proportional to that for the U.S. subpopulation, during the 12-year period. Using the CONV arm data (years 0 to 4), we estimated the conventional arm versus U.S. age-adjusted HR to be 4.54. Equivalently, the CONV arm survival curve is exponential on an accelerated time scale that reflects yearly increases in hazard rates for the matched U.S. subpopulation. This model fit the available data well (with two goodness of fit tests each yielding p > 0.6), but projections beyond 3.5 years are speculative.
To project survival in the ICD arm, we used three alternative, but related, methods, depending on the choice of the HR relative to CONV. For each, the HR at year 3.5 was fixed at 0.677, the data-based estimate. The three scenarios for the ICD HR relative to CONV were:
- 1 ICD1, where HR remains the same as that observed during the trial;
- 2 ICD2, where HR increases linearly after 3.5 years so that at 12 years ICD survivors have the same risk as do CONV survivors, which is consistent with an assumption that the beneficial advantage of the ICD declines, relative to a CONV population with patients at risk of sudden cardiac death gradually dying off;
- 3 ICD3, where HR increases faster after 3.5 years so that the survival curves meet at 12 years, which is consistent with an assumption of greater mortality risk among survivors in the ICD arm than in the CONV arm after 7.1 years.
Because of linear changes over the course of time, the ICD2-3 models have cubic hazard rates.
Projecting costs. We first conducted regression analyses of monthly patient-specific costs (undiscounted and excluding device, implantation, and replacement costs for ICD-arm patients). The regression model consisted of arm-specific random effects for patients (excluding initial and death costs), and arm-specific fixed effects for costs in the first month and for the six-month period before death. We originally considered more detailed initial costs and death costs, and time trends in monthly costs, but we found these to be small and statistically insignificant.
We then used the fitted regression model to project monthly costs beyond 3.5 years, multiplying the estimated arm-specific monthly costs (discounted) by the estimated probability of survival through that month, using the corresponding survival models. Because time trends could not be identified, cost projections for survivors do not increase with age, except that death costs become more likely with increasing death rates. In the projections, we added in generator replacement costs of $27,414, based on generator and associated medical cost data from 32 early replacements. Replacement costs, appropriately discounted, were assumed to take place at years 5 and 10; to assess sensitivity to this assumption, we considered a 7-year replacement period for the ICD1 scenario.
Projecting the iCER. For any time point horizon, the projected iCER is obtained as the differential (ICD minus CONV) projected discounted accumulated cost up to the horizon, divided by the corresponding projected discounted years-of-life saved (YOLS). We limited projections to 12 years because assumptions about long-term survival, ICD effects, and costs become increasingly tenuous the longer the projection, but this period should be long enough to capture much of the potential lifetime implications. (This choice also avoided ending at generator replacement times, multiples of 5 [or 7] years.)
Subgroup and sensitivity analyses
We analyzed the following:
- 1 comparing patients in several clinically significant subgroups;
- 2 including, for the survival component of the analysis, the 137 patients with no cost data, bringing the total number of patients to 1,232;
- 3 removal of the costs of electrophysiologic testing from all ICD arm patients (because this generally is not required for an ICD implantation but was recommended in the MADIT-II protocol);
- 4 reduction of the initial and replacement ICD device costs by 50%.
We examined outlier costs and found them to be reasonably balanced between the two arms. However, 10 patients in the ICD arm had heart transplants whereas none of the patients in the CONV arm did. For these 10 hospitalizations, costs averaged $117,800 but did not constitute the extreme cost hospitalizations, nor was the effect large when averaged over all ICD-arm patients or over all months of follow-up.
|
Results
|
|---|
Primary analyses.
Table 2 summarizes the medical care use and costs for patients in each arm. On average, the device and associated implantation costs for ICD patients who received an implant totaled $32,578. Average monthly costs were higher for ICD patients—including the costs of any device-related adverse events ($1,489 vs. $1,357)—with all utilization categories, particularly inpatient hospital services ($813 vs. $735), contributing to the difference. Costs were substantially higher in the six months before a patient's death. None of the differences in monthly costs between treatment arms were statistically significant.
Table 3 presents the within-trial results. At 3.5 years, there was a $39,200 (discounted) accumulated cost difference between the two arms. Patients in the ICD arm are expected to live two months longer within 3.5 years (0.167 discounted YOLS). The iCER was $235,000/YOLS, with a 95% confidence interval of $121,000 to $1,212,000/YOLS, the very large upper limit reflecting the small lower limit on YOLS (0.033 years). The iCER calculated by the alternative methodology (18), as in the MADIT study (17), was $230,000/YOLS. The calculated iCERs over time appear in Figure 1.
View larger version (11K):
[in this window]
[in a new window]
|
Figure 1 Incremental cost-effectiveness ratios (iCERs) for various horizons, actual and projected. The iCER was estimated from the data with horizons of 1, 1.5, 2, 2.5, 3, and 3.5 years, marked by circles. The vertical line segment is a 95% confidence interval for the iCER at 3.5 years (Table 3). The other lines are iCERs derived from projected survival curves (this figure) and the regression model for costs (Fig. 2). As in Figure 2, the actual iCER values are slightly higher than the fitted model projections because early replacement costs of implantable cardioverter-defibrillators were removed when fitting the model, with all replacement costs imposed at 5 and 10 years. Note that the vertical axis has a logarithmic scale.
|
|
Projecting to a 12-year time horizon.
Figure 2 displays actual survival for the first 3.5 years and projects it 12 years after randomization for the CONV arm and for the three ICD scenarios described previously. At year 12, projected survival is 25.7%, 19.5%, or 13.4%, depending on the assumptions and the arm; the corresponding YOLS values (discounted) at year 12 are 1.048, 0.871, and 0.665 for ICD1 to ICD3, respectively.
View larger version (11K):
[in this window]
[in a new window]
|
Figure 2 Survival curves, actual and projected. For the first 3.5 years, the two curves are the Kaplan-Meier estimates of the probability of survival in the implantable cardioverter-defibrillator (ICD) and conventional-therapy (CONV) arms, based on 1,095 patients in this cost study. From 3.5 years onward, the CONV survival curve has been projected assuming proportional hazards with an age- and gender-matched U.S. subpopulation, with a hazard ratio of 4.54. There are three projected ICD survival curves, ICD1 with hazard rates relative to CONV equal to 0.677 throughout, ICD2 with this hazard ratio increasing linearly to unity at 12 years, and ICD3 with the HR increasing to 1.44 at 12 years, reaching 1.0 at 7.1 years; see the text for rationales for these choices. Years-of-life saved are the areas between ICD and CONV curves.
|
|
The cost projections are based on a regression analysis of undiscounted monthly cost data that found three cost components: 1) initial month cost (estimated as $10,335, plus device cost of $21,713, for ICD arm patients and $1,142 for CONV arm patients); 2) average monthly costs subsequently ($1,186 for ICD, $1,033 for CONV—with no evidence of increase over time); and 3) 6-month prior-to-death additional costs of $29,236 ($15,130 in the last month, $3,970 and $1,098 in each of for months 2 to 4 and 5 to 6, respectively). Death costs were highly variable and without statistically significant differences between arms, but we used arm-specific monthly costs to achieve a better fit.
Figure 3 displays discounted cumulative costs, actual values until 3.5 years and projected values beyond, based on the same four assumed trajectories. Projected values, based on the regression formulae, also are plotted for the period up to 3.5 years, demonstrating the quality of their fit. Periodic increases in costs for the ICD occur when replacement devices are implanted; otherwise, the increases in the two arms are almost parallel. The three ICD curves largely overlap until year 10. At year 12, discounted cumulative costs were $180,300, $177,400 and $173,700 for the ICD1 to ICD3 scenarios, as opposed to $97,900 for the CONV arm.
View larger version (11K):
[in this window]
[in a new window]
|
Figure 3 Cumulative discounted costs, actual and projected. Actual cumulative discounted costs are plotted for the implantable cardioverter-defibrillator (ICD) and conventional-therapy (CONV) arms up to 3.5 years. Projected costs are based on a regression model and plotted over the range from 0 to 12 years; up to 3.5 years, they use the regression model for costs together with Kaplan-Meier estimates of survival, whereas after 3.5 years, there are three variations for the ICD arm projections, corresponding to three assumptions about projected survival, and one CONV arm projection (Fig. 1 legend). The actual ICD arm costs are slightly higher than the projected values because, in projections, the costs of 32 replacement ICDs that occurred in the observation period were removed (to fit a regression model), and all replacement costs were assumed to occur at exactly 5 and 10 years, resulting in jumps in the ICD arm curves at those times. The jump near the origin is caused by the initial ICD implantation.
|
|
Figure 1 displays the corresponding iCER curves, which decrease with increasing time except for increases at years 5 and 10 with device replacement. The iCERs at year 12 for ICD1 to ICD3 versus CONV are $78,600, $91,300 and $114,000/YOLS, respectively. If generator replacements take place at seven-year intervals, the iCER at year 12 (ICD1 vs. CONV) would be $66,700/YOLS, a 15% reduction.
Subgroup and sensitivity analyses.
We estimated the iCER in each of five pairs of subgroups shown in Table 4. Four of the ten subgroups—namely, age  65 years, New York Heart Association functional class II or greater, QRS 120, blood urea nitrogen >25 mg/dl—had a statistically significant difference (between treatment arms) in life expectancy at 3.5 years, or equivalently, a significantly positive YOLS; confidence limits are problematic when YOLS may be negative. For each of these four pairs of subgroups, the subgroup with the higher mortality risk had the higher YOLS and lower iCER. However, none of the comparisons of differences between arms within a pair are statistically significant.
Reinstatement of the 137 patients with no cost data led to an estimated iCER of $211,000/YOLS (95% confidence interval $116,000 to $673,000) (16). The reduced iCER and upper confidence limit is due to greater ICD effectiveness found in the European centers and the increased sample size but assumes similar patterns of survival and costs across patient groups with and without cost data.
Removing the costs of initial electrophysiologic studies, for the 506 patients in the ICD arm who had them (average costs = $1,259), reduced the iCER at 3.5 years to $229,000/YOLS, a 2.6% reduction. Reducing ICD device costs by 50% resulted in an iCER of $166,000/YOLS at 3.5 years, a 29% reduction.
|
Discussion
|
|---|
Both the effectiveness and cost-effectiveness results from randomized controlled trials are intended to provide information for clinical policy. The results of this study reveal a dilemma in presenting cost-effectiveness results from such trials. Whereas the effectiveness results are largely self-sufficient, demonstrating that the ICD reduces mortality for the MADIT-II study population, the cost-effectiveness data are more difficult to interpret. The cost and benefit data are observed for a relatively short period, whereas it is lifetime costs and benefits that policymakers need to calculate the true cost effectiveness of an intervention. A further complication is that, for interventions like the MADIT-II study where the incremental costs are largely the result of the initial intervention but benefits continue to accrue, iCER falls rapidly with time horizon (20). Thus, the within-trial iCER is a poor estimate of the lifetime value. This dilemma was not as acute for previous ICD trials because their within-study iCERs were much lower; their projected iCERs were not as significant in interpreting their policy implications (17,21,22). For example, the MADIT study cost for four-year iCER was $27,000/YOLS (17) resulting from a combination of a much greater YOLS and higher costs in the CONV patients. The MADIT-II study results bring both the need for, and uncertainty of, these projections clearly to the fore.
Significant issues are certainly at stake. Implantable cardioverter-defibrillators have been shown to substantially reduce the number of sudden cardiac deaths (1–8), but their costliness makes it essential that they be targeted to populations for whom they confer substantial benefits. Using the Centers for Medicare and Medicaid Services estimates (9) of the MADIT-II study population in the U.S. (55,000 to 65,000 new cases yearly), our 12-year projections of incremental costs ($78,600 to $114,000) suggest additional annual expenditures in excess of $5 billion.
With such large additional expenditures at stake, clinical policymakers, whether physicians making treatment decisions or insurers making coverage decisions, must consider the cost-effectiveness results in their considerations despite their inherent uncertainty. The iCER at 3.5 years, the time horizon for the MADIT-II study, was $235,000/YOLS. The relatively high estimate of the iCER is largely the result of the high initial cost of implantation and the relatively small YOLS, the latter partially reflecting the underlying heterogeneity of the MADIT-II study population and the significant risks of nonarrhythmic death (40% of the classifiable deaths in CONV patients were assigned to other causes) (23). The heterogeneity in response appears clearly in the subgroup analyses. Although the study was not designed for this purpose, these analyses suggest that the iCER is more favorable in higher-risk subgroups. It would be important to confirm this finding in other studies and over a longer time horizon.
Given the limited usefulness of the within-trial iCER in informing policy, we developed three projection scenarios to represent the uncertainties implicit in any attempt to assess the longer term effects of ICD implantation: ICD1, where the protective effect continues unabated—optimistic considering that other causes of death will have an increasing role with aging; ICD2, where it gradually disappears; and ICD3, where the ICD death rate grows to surpass that in the conventional arm—which is pessimistic, with cumulative mortality "catching up" at 12 years (8 years in Weiss et al. [24]). We projected costs as if the data-based regression formula applies into the future. The corresponding iCERs at 12 years ranged from $78,600 to $114,000/YOLS. Given the uncertainties in knowledge currently available, particularly on the long-term survival curve for the MADIT-II study population, there is no guarantee that the "true" iCER would fall in that range.
The BlueCross-BlueShield study (11), a recent revision of it (12), and a recent Duke study (10) provide useful comparisons, using different methodologies applied to previously published MADIT-II study survival results. The BCBS Markov decision model approach (11) was based on the MADIT-II study cause-specific mortality data but with cost data taken from non-MADIT study sources. Lifetime iCER was estimated to be $36,700/YOLS, with corresponding values at 3.5 and 12 years, decreasing from $178,900 to $49,600/YOLS (G. Sanders, personal communication, November 2004). Their model-based 3.5-year iCER was 24% lower than our fully data-based value. Our ICD1 scenario with a seven-year replacement period provides the most direct comparison of their 12-year estimates, both assuming a continuing protective effect. Their $49,600/YOLS is lower than our estimate ($66,700/YOLS) by a similar proportion (26%).
The recent revision (12) used all-cause mortality, some revision of costs (derived from non-MADIT study sources), and a five-year replacement period, and estimated a $39,000/YOLS lifetime iCER. Their cost projections, for both arms, remain substantially below our patient-based values, with $57,500 (2005 dollars) lifetime costs in the control group substantially lower than even our $97,900 (2001 dollars) at 12 years (and we have not allowed for any increase in costs with aging).
The Duke study (10) was based on up to 15 years of cost and survival data for a MADIT-II study-eligible group of Duke University Medical Center patients. The ICD "comparison group" experience was generated assuming an HR of 0.69 forever and non-ICD costs identical to those for non-ICD patients. Lifetime and 12-year iCERs were $50,500/YOLS and $79,900/YOLS, respectively. Their 12-year value was almost identical to ours for ICD1 (also with a persisting ICD effect). Applying the mean of the ratios between 12-year and lifetime iCERs of these two studies (1.47) to our 12-year value suggests an estimated lifetime iCER in the $50,000 to $100,000/YOLS range.
Each of these studies assumed identical (nondevice) costs in the two arms, whereas we found higher costs in ICD survivors than in CONV survivors, possibly the result of an excess of hospitalizations for heart failure in the ICD arm (Moss et al. [5]). These discrepancies confirm the difficulties in: 1) basing estimates on data from different source, and 2) long-term extrapolations.
We have not translated into iCERs based on quality-adjusted life-years (QALYs). Some studies have done so somewhat arbitrarily, e.g., in Sanders et al. (12), it was assumed that QALYs averaged 0.80 at baseline with later reductions with aging, resulting in lifetime YOLS being reduced by a factor of 0.73 when converted to QALYs. By contrast, in the MADIT-II study, QALYs at baseline averaged only 0.64 (K. Noyes, unpublished observations, January 2006). Of necessity, iCERs in QALYs will be greater.
Using iCERs as $/QALY rather than $/YOLS leads to values higher than the conventional limit for cost effectiveness ($50,000 to 100,000 per QALY), but it is not clear whether generally accepted medical practices are, or should be, within these limits. For example, the National Heart, Lung, and Blood Institute Adult Treatment Panel III guidelines recommend cholesterol-lowering treatments with iCERs that are substantially higher than $100,000 per QALY (25). Furthermore, these limits have been challenged on conceptual grounds since they have not changed over time with per capita income and medical prices, key determinants of the value of a YOLS (26,27). Clearly, a greater consensus is needed as to a threshold value that would indicate whether or not an intervention is cost effective.
The large uncertainties that policymakers must confront can be reduced with better estimates of the ICD effects on long-term survival and on costs, especially by clinically significant subpopulations. In the interim, policy makers will have to apply the available knowledge for decisions as to how to best use this promising new technology.
|
Acknowledgments
|
|---|
We acknowledge the commitment of Guidant in maintaining the independence of our study. We are indebted to the patients in the study, to the physicians who referred their patients to the study, and to the center investigators and study coordinators who collected the data. Data collection was greatly facilitated by the cooperation of the MADIT-II Coordination and Data Center under the direction of Mary W. Brown.
|
Footnotes
|
|---|
Several authors (Dr. Hall, Dr. Dick, Mr. Zhao, Ms. Hahn, Mr. Andrews, Dr. Moss) are significant participants on a research study funded by Guidant Corp. (MADIT-CRT). This study was supported by a grant from the Guidant Corporation of St. Paul, Minnesota, to the University of Rochester. Dr. Zwanziger is now at the School of Public Health, University of Illinois at Chicago; Dr. Mushlin is now at the Weill School of Medicine, Cornell University.
|
References
|
|---|
1. Moss AJ, Hall WJ, Cannom DS, et al. MADIT Investigators Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia N Engl J Med 1996;335:1933-1940.[Abstract/Free Full Text]2. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias N Engl J Med 1997;337:1576-1583.[Abstract/Free Full Text] 3. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prytowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery diseaseMulticenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-1890.[Abstract/Free Full Text] 4. Connolly SJ, Gent M, Roberts RS, et al. CIDS Investigators Canadian Implantable Defibrillator Study (CIDS)A randomized trial of the implantable cardioverter-defibrillator against amiodarone. Circulation 2000;101:1297-1302.[Abstract/Free Full Text] 5. Moss AJ, Zareba W, Hall WJ, et al. MADIT-II Investigators Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med 2002;346:877-883.[Abstract/Free Full Text] 6. Bristow MR, Saxon LA, Boehmer J, et al. COMPANION Investigators Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 2004;350:2140-2150.[Abstract/Free Full Text] 7. Kadish A, Dyer A, Daubert JP, et al. DEFINITE Investigators Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy N Engl J Med 2004;350:2151-2158.[Abstract/Free Full Text] 8. Bardy G, Lee KL, Mark DB, et al. SCD-HeFT Investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 2005;352:225-237.[Abstract/Free Full Text] 9. Centers for Medicare and Medicaid Services. Decision Memorandum: National Coverage Determination (NCD) on Implantable Defibrillators, June 6, 2003, pp 1–37http://www.cms.hhs.gov/determinationprocess/downloads/id39-5.pdf 2005Accessed April 12, 2006. 10. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II Ann Intern Med 2005;142:593-600.[Abstract/Free Full Text] 11. Technology Evaluation Center; BlueCross-BlueShield Association. Special report: cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population. 2004;19:1–23http://www.bcbs.com/tec/vol19/19_03.html 2005Accessed April 12, 2006. 12. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators N Engl J Med 2005;353:1471-1480.[Abstract/Free Full Text] 13. Mushlin AI, Zwanziger J, Gajary E, Andrews M, Marron R. Approach to cost-effectiveness assessment in the MADIT trial Am J Cardiol 1997;80:33F-41F.[CrossRef][Medline] 14. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB, Panel on Cost-Effectiveness in Health and Medicine Recommendations of the Panel on Cost-Effectiveness in Health and Medicine JAMA 1996;276:1253-1258.[Abstract/Free Full Text] 15. Zhao H, Tian L. On estimating medical cost and incremental cost-effectiveness ratios with censored data Biometrics 2001;57:1002-1008.[CrossRef][Web of Science][Medline] 16. Wang H, Zhao H. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data. Biometrics 2006. In Press.. 17. Mushlin AI, Hall WJ, Zwanziger J, et al. MADIT Investigators The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT Circulation 1998;97:2129-2135.[Abstract/Free Full Text] 18. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data Biometrics 1997;53:419-434.[CrossRef][Web of Science][Medline] 19. Anderson RN, DeTurk PB. United States life tables, 1999. National Vital Statistics Reports 2002;50, Hyattsville, MD: National Center for Health Statistics. Tables 5 and 6. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr50/nvsr50_06.pdf. Accessed April 12, 2006.. 20. Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, Piepoli M, Francis DP. Life-years gained from defibrillator implantation: markedly nonlinear increase during 3 years of follow-up and its implications Circulation 2004;109:1848-1853.[Abstract/Free Full Text] 21. Larsen G, Hallstrom A, McAnulty J, et al. AVID Investigators Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy Circulation 2002;105:2049-2057.[Abstract/Free Full Text] 22. O'Brien BJ, Connolly SJ, Goeree R, et al. CIDS Investigators Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS) Circulation 2001;103:1416-1421.[Abstract/Free Full Text] 23. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, MADIT-II Investigators Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) J Am Coll Cardiol 2004;43:1459-1465.[Abstract/Free Full Text] 24. Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias Am J Med 2002;112:519-527.[CrossRef][Web of Science][Medline] 25. Prosser LA, Stinnett AA, Goldman PA, et al. Cost effectiveness of cholesterol-lowering therapies according to selected patient characteristics Ann Intern Med 2000;132:769-779.[Abstract/Free Full Text] 26. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard Med Decis Making 2000;20:332-342.[Abstract/Free Full Text] 27. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641.[Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
E. M. Kanoupakis, E. G. Manios, and P. E. Vardas
Predicting future shocks in implantable cardioverter defibrillator recipients: the role of biomarkers
Europace,
November 1, 2009;
11(11):
1434 - 1439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Cowie and on behalf of the co-authors
Editorial: The economical challenge in the treatment of chronic heart failure: is primary prophylactic implantable cardioverter defibrillator therapy cost-effective in Europe?
Europace,
October 1, 2009;
11(10):
1407 - 1408.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Meine, T. Smith, and R. N.W. Hauer
The economical challenge in the treatment of chronic heart failure: is primary prophylactic ICD therapy cost-effective in Europe? Reply
Europace,
October 1, 2009;
11(10):
1408 - 1410.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ghanbari, G. Dalloul, R. Hasan, M. Daccarett, S. Saba, S. David, and C. Machado
Effectiveness of Implantable Cardioverter-Defibrillators for the Primary Prevention of Sudden Cardiac Death in Women With Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials
Arch Intern Med,
September 14, 2009;
169(16):
1500 - 1506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tung and C. D. Swerdlow
Refining Patient Selection for Primary Prevention Implantable Cardioverter-Defibrillator Therapy: Reeling in a Net Cast Too Widely
Circulation,
September 8, 2009;
120(10):
825 - 827.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Myerburg, V. Reddy, and A. Castellanos
Indications for implantable cardioverter-defibrillators based on evidence and judgment.
J. Am. Coll. Cardiol.,
August 25, 2009;
54(9):
747 - 763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zaman, G. Sivagangabalan, A. Narayan, A. Thiagalingam, D. L. Ross, and P. Kovoor
Outcomes of Early Risk Stratification and Targeted Implantable Cardioverter-Defibrillator Implantation After ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
Circulation,
July 21, 2009;
120(3):
194 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Cowie, D. Marshall, M. Drummond, N. Ferko, M. Maschio, M. Ekman, L. de Roy, H. Heidbuchel, Y. Verboven, F. Braunschweig, et al.
Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population
Europace,
June 1, 2009;
11(6):
716 - 726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Meine, T. Smith, and R. N.W. Hauer
The economical challenge in the treatment of chronic heart failure: is primary prophylactic ICD therapy cost-effective in Europe?
Europace,
June 1, 2009;
11(6):
689 - 691.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Boriani, M. Biffi, C. Martignani, I. Diemberger, C. Valzania, M. Bertini, and A. Branzi
Expenditure and value for money: the challenge of implantable cardioverter defibrillators
QJM,
May 1, 2009;
102(5):
349 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Costantini, S. H. Hohnloser, M. M. Kirk, B. B. Lerman, J. H. Baker II, B. Sethuraman, M. M. Dettmer, D. S. Rosenbaum, and for the ABCD Trial Investigators
The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.
J. Am. Coll. Cardiol.,
February 10, 2009;
53(6):
471 - 479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Cohen and M. R. Reynolds
Interpreting the results of cost-effectiveness studies.
J. Am. Coll. Cardiol.,
December 16, 2008;
52(25):
2119 - 2126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Chow, D. J. Kereiakes, J. Onufer, A. Woelfel, S. Gursoy, B. J. Peterson, M. L. Brown, W. Pu, D. G. Benditt, and on behalf of the MASTER Trial Investigators
Does Microvolt T-Wave Alternans Testing Predict Ventricular Tachyarrhythmias in Patients With Ischemic Cardiomyopathy and Prophylactic Defibrillators?: The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) Trial
J. Am. Coll. Cardiol.,
November 11, 2008;
52(20):
1607 - 1615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Pellegrini, K. Lee, J. E. Olgin, M. P. Turakhia, Z. H. Tseng, R. Lee, N. Badhwar, B. Lee, and P. D. Varosy
Impact of advanced age on survival in patients with implantable cardioverter defibrillators
Europace,
November 1, 2008;
10(11):
1296 - 1301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tung, P. Zimetbaum, and M. E. Josephson
A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1111 - 1121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein
Benefits of the Implantable Cardioverter-Defibrillator
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1122 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ding, W. Hua, H. Niu, K. Chen, and S. Zhang
Primary prevention of sudden cardiac death using implantable cardioverter defibrillators
Europace,
September 1, 2008;
10(9):
1034 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Goldenberg and A. J. Moss
Long QT syndrome.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2291 - 2300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
e1 - e62.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. Mark Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2085 - 2105.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation,
May 27, 2008;
117(21):
2820 - 2840.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation,
May 27, 2008;
117(21):
e350 - e408.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Bach
Cost Sharing for Health Care -- Whose Skin? Which Game?
N. Engl. J. Med.,
January 24, 2008;
358(4):
411 - 413.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Goldenberg, A. K. Vyas, W. J. Hall, A. J. Moss, H. Wang, H. He, W. Zareba, S. McNitt, M. L. Andrews, and for the MADIT-II Investigators
Risk Stratification for Primary Implantation of a Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction
J. Am. Coll. Cardiol.,
January 22, 2008;
51(3):
288 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sleight
New Methods for Risk Stratification in Patients After Myocardial Infarction: Autonomic Control and Substrate Sensitivity
J. Am. Coll. Cardiol.,
December 11, 2007;
50(24):
2291 - 2293.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Krumholz and F. A. Masoudi
The Year in Epidemiology, Health Services Research, and Outcomes Research
J. Am. Coll. Cardiol.,
December 4, 2007;
50(23):
2254 - 2262.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ezekowitz, B. H. Rowe, D. M. Dryden, N. Hooton, B. Vandermeer, C. Spooner, and F. A. McAlister
Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction
Ann Intern Med,
August 21, 2007;
147(4):
251 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Passman and A. Kadish
Sudden Death Prevention With Implantable Devices
Circulation,
July 31, 2007;
116(5):
561 - 571.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Zimetbaum
A 59-Year-Old Man Considering Implantation of a Cardiac Defibrillator
JAMA,
May 2, 2007;
297(17):
1909 - 1916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Heidbuchel
The cost of implantable defibrillators: how the perception of reality depends on perspective
Eur. Heart J.,
February 8, 2007;
(2007)
ehl518v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Hlatky and D. B. Mark
The high cost of implantable defibrillators
Eur. Heart J.,
February 2, 2007;
28(4):
388 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. W. Stevenson
Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Death in Heart Failure: Are There Enough Bangs for the Bucks?
Circulation,
July 11, 2006;
114(2):
101 - 103.
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods